B7-33 Research Hub

The B-chain of the human peptide hormone relaxin-2 (H2 relaxin) is the source of the synthetic single-chain peptide counterpart B7-33. It was created using logical peptide design to mimic some of the native hormone's structural and functional traits while providing a more straightforward molecular structure than the two-chain parent protein. B7-33 is a short synthetic peptide made via Solid Phase Peptide Synthesis (SPPS), in contrast to recombinant relaxin-2, which is made up of A- and B-chains connected by disulphide linkages.

The peptide originated from structure–function studies investigating the receptor-binding properties of relaxin-2 and the contribution of its B-chain to receptor recognition. These investigations led to the development of B7-33 as a research tool for examining relaxin family peptide signalling and receptor pharmacology. Since its initial characterisation, B7-33 has been recognised in experimental research for studies exploring relaxin receptor interactions, ligand binding and intracellular signalling associated with the relaxin family peptide receptor 1 (RXFP1).

Within laboratory settings, B7-33 is investigated using biochemical assays, cultured cell systems and preclinical experimental models to characterise its molecular interactions and pharmacological profile. As a synthetic peptide analogue, it is routinely analysed using high-performance liquid chromatography (HPLC) to verify purity and liquid chromatography–mass spectrometry (LC-MS) to confirm molecular identity. Batch-specific Certificates of Analysis (CoAs) provide traceable documentation of peptide identity, purity and analytical quality prior to research use.

The B-chain of human relaxin-2 (H2 relaxin) is the source of the synthetic peptide counterpart B7-33. Its main structure is made up of a brief linear amino acid sequence that was designed to simplify the overall molecular architecture while preserving important receptor-binding characteristics of the native hormone. B7-33 is a single-chain peptide produced by Solid Phase Peptide Synthesis (SPPS), in contrast to human relaxin-2, which is made up of two peptide chains (A- and B-chains) connected by disulphide linkages.

B7-33 does not take on the intricate tertiary structure typical of the full-length relaxin protein because of its comparatively short sequence. Rather, it mostly resides as a flexible peptide in solution, with transient secondary structural components that are affected by solvent content, pH, and ionic strength.

The physicochemical properties of B7-33 are determined by its amino acid composition, including the distribution of charged, polar and hydrophobic residues, which influence its net charge, hydrophilicity and chromatographic behaviour. Compared to recombinant relaxin proteins, B7-33's synthetic peptide equivalent does not experience post-translational modifications like glycosylation, making analytical characterization easier. It should be handled in a lab setting to maintain structural integrity since, like other short synthetic peptides, it is prone to proteolytic degradation. Peptide identity, purity and molecular mass are routinely confirmed using analytical techniques including high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS) prior to release for research applications.

Recent research has focused on B7-33, a synthetic peptide analogue made from the B-chain of human relaxin-2 (H2 relaxin). The peptide preserves key receptor-binding properties of the natural hormone despite having a simplified single-chain structure, according to published experimental results. Research has mostly focused on its interaction with relaxin family peptide receptor 1 (RXFP1) and the downstream signaling pathways associated with receptor activation.

In vitro models have explored the interaction of B7-33 with RXFP1 using receptor-binding assays, recombinant expression systems and cultured mammalian cells. Structural and pharmacological studies have examined ligand recognition, receptor affinity and signal transduction to better understand how the peptide engages the receptor compared with full-length relaxin-2. Experimental investigations have also characterised biased agonism, examining whether B7-33 preferentially engages selected intracellular signalling pathways following receptor activation.

Published studies have investigated several downstream signalling networks associated with B7-33 following interaction with RXFP1. Experimental models have examined signalling involving extracellular signal-regulated kinase (ERK1/2), cyclic adenosine monophosphate (cAMP) and nitric oxide-associated pathways using phosphorylation assays, reporter gene analyses and biochemical techniques. These investigations have focused on characterising receptor-mediated intracellular communication and the molecular events that follow ligand binding under controlled laboratory conditions.

Current laboratory investigations have also examined receptor internalisation, ligand–receptor kinetics and intracellular trafficking following exposure to B7-33. Cell-based studies have utilised fluorescence microscopy, recombinant receptor systems and molecular biology techniques to investigate receptor localisation, signal duration and protein–protein interactions associated with RXFP1 activation.

The molecular mechanism of B7-33 continues to be investigated through structural biology, receptor pharmacology and preclinical experimental research. Published evidence characterises the peptide as a selective relaxin-2 analogue whose principal area of investigation centres on RXFP1-mediated signalling, ligand–receptor interactions and the characterisation of downstream intracellular pathways. Although several signalling mechanisms have been described in experimental models, ongoing research continues to define the structural determinants of receptor activation and pathway selectivity.

Solid Phase Peptide Synthesis (SPPS) is commonly used to produce B7-33, a synthetic peptide analogue. After synthesis, shortened peptide sequences, residual synthesis reagents, and other process-related impurities can be removed from the crude peptide through purification, most commonly using preparative high-performance liquid chromatography (HPLC).

Analytical high-performance liquid chromatography (HPLC) can be used to assess peptide purity and evaluate batch consistency, while liquid chromatography–mass spectrometry (LC-MS) can be used to confirm peptide identity and molecular mass. Other analytical techniques, such as peptide mapping or amino acid analysis, may be used when needed to characterize the peptide sequence and composition.

Batch number, peptide identity, purity, molecular mass, and other quality-control information can be documented in a Certificate of Analysis (COA).

Store B7-33 at 2–8°C in accordance with the current batch documentation. Keep the lyophilized material protected from moisture, excessive heat, and direct light during storage and shipping.

For laboratory handling, keep the material in its original container and limit unnecessary exposure to environmental conditions. Handle the peptide under appropriate laboratory conditions to help maintain its physical and analytical integrity.